Mary Caffrey

The advocacy group said the type 1 diabetes community is concerned about the payer's decision because not every device works the same way for every person. After a 2016 policy change affecting adults, 2 pump makers pulled devices from the US market, although other innovation has continued.

FDA has launched a process that will give real-world data generated outside clinical trials more importance than it’s had in the past—with implications for payers, drug companies, and most of all, patients.

Rates of maternal deaths have climbed over a generation in the United States while falling in other developed countries. African American women are more than 3 times more likely to die in childbirth than white women. A new federal law and efforts in states like New Jersey seek to turn the tide.

The study followed more than 2300 men and women for 5 years and found different patterns of depression symptoms between the genders.

The study appeared as one of its authors testified before Congress on the high cost of prescription drugs, including insulin. Experts told the House Committee on Oversight and Reform that branded drug makers enjoy monopolies and that barriers to competition harm consumers.

The National Institutes of Health halted the landmark SPRINT study in 2015 after results clearly showed a cardiovascular benefit for patients who had their systolic blood pressure aggressively controlled to 120 mm/Hg.

The study counted all kinds of activity, including walking to work, repairs around the house, and, of course, sports.

The partnership will seek repeatable, scalable models to present at a summit later this year.

A nurse at the Cleveland Clinic launched the initiative after mothers asked to delay their newborns' baths to increase their ability to take to nursing.

The study is first to measure sleep along with spread of atherosclerosis throughout the body, according to the American College of Cardiology.

Keeping patients with diabetes motivated is the most challenging part of exercise, the authors say, as they call for psychologists and counselors to be part of the care team.

While depression and diabetes have been linked previously, the study from Hong Kong examined the effects of an early diagnosis of type 2 diabetes on hospitalization over time.

Authors noted that because experiments are typically done only on male mice, this brain signaling pathway controlling bone growth had never been discovered.

Rather than offer support, physicians often reinforced the women's feeling of not being in control of their decisions, according to a study looking at why obese women are less likely to start or keep breastfeeding.

The analysis discusses the strength of evidence that SGLT2 inhibitors have a class effect in preventing heart failure for patients with diabetes.

Research and regulatory gaps in the use of marijuana will only grow unless the scientific community and policy leaders fill the void, according to a commentary series in Annals of Internal Medicine on marijuana’s rising availability.

The initial trial made news because the results were at odds with ACCORD. This new analysis highlights the need for personalized diabetes care, especially among older adults.

Publishing a list of conditions for which long-acting birth control is medically indicated increased uptake among women in Medicaid, but overall use remains low.

Findings in Hypertension, published by the American Heart Association, suggest a need to identify those at early risk of dementia.

With everyone carrying a smartphone, there's no reason why digital health tools and apps cannot be leveraged to hold at-risk patients accountable for cardiovascular health.

A statement on hypoglycemia, an consensus document from cardiologists on diabetes and CVD, and guidelines on treating cholesterol.

The Commonwealth Fund report compared the status of health and healthcare for women in the United States to that of 10 other wealthy countries, including the United Kingdom, Canada, Germany, and Australia.

Concerns over cost should lead FDA to recommend adjustments to these trials, which many say have led to unexpected knowledge and changed the field of diabetes care.

From chimeric antigen receptor T-cell therapy to value-based contracting, reimbursement issues dominated reader interest.

Leading cardiologist Mikhail N. Kosiborod, MD, FACC, FAHA, discusses how the FDA's 2008 guidance requiring cardiovascular outcomes trials has changed the treatment landscape in diabetes care and what expectations might look like going forward.

Technology and issues with reimbursement with of interest to authors writing for our diabetes journal this year.

Dublin, Ireland-based S3 Connected Health discusses the need to identify barriers to healthy behavior as well as factors that can promote healthy actions.

The COORDINATE-Diabetes seeks to explore what happens between development of clinical guidelines and their translation into clinical practice.